Current Novartis chair Jörg Reinhardt will not stand for re-election in 2025 after a 12-year term of office and will retire as planned.
Keystone / Georgios Kefalas
Change is afoot in the upper echelons of Novartis, with Giovanni Caforio set to be elected as the next chair of its board of directors at the 2025 Annual General Meeting.
He will replace current chair Jörg Reinhardt, who will not stand for re-election in 2025 after a 12-year term of office and will retire as planned.
New chair designate Caforio has spent a large part of his professional career at Bristol Myers Squibb (BMS). He was CEO from May 2015 to November 2023 and served as executive chair from May 2017 to March 2024.
Under his leadership, BMS successfully transformed itself into a global medicines company with strong capabilities in research and development as well as commercialisation, Novartis wrote in a statement on Tuesday.
Caforio was born in Italy and is a trained physician. He holds both Italian and US citizenship, and speaks fluent Italian, French, Spanish, Portuguese, and English.
Adapted from German by DeepL/kp/sb
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
Novartis announces billion-dollar investments in the US
This content was published on
Swiss pharmaceutical company Novartis plans to invest a total of $23 billion in the US over the next five years to expand production and research.
Money laundering and paedophile crime increase in Switzerland
This content was published on
The number of suspected cases of money laundering, reports of threats against officers and cases of paedophile crime increased last year, in some cases sharply.
Toblerone invests in Bern and puts new emphasis on Swiss cross
This content was published on
Since US multinational Mondelēz relocated part of Toblerone production to Slovakia in 2023, the company is no longer allowed to call its chocolate “Swiss made”.
Switzerland and 35 other members declare support for WTO
This content was published on
Switzerland and 35 other members have recommitted themselves to honouring the rules of the Geneva-based World Trade Organization (WTO).
This content was published on
The majority of Swiss respondents painted a negative picture of US President Donald Trump, according to a survey. Women were even more critical of him than men.
Controversial Russian soprano Anna Netrebko returns to Zurich
This content was published on
Russian soprano Anna Netrebko, who is said to be close to Russian president Vladimir Putin, to perform at the Zurich Opera House.
This content was published on
Multiple births following artificial insemination in Switzerland have fallen sharply over the last 20 years, shrinking from 17.4% in 2002 to 2.8% in 2023.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Pharma: Novartis announces job cuts in the development division
This content was published on
In Switzerland, 400 to 440 positions in the company's development division are likely to fall victim to the measures over the next two to three years.
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure - it’s a turning point for Novartis.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.